YDES
Neutral signalScored 2026-09-10 Drivers: fundamentals. Moteurs : fondamentaux.
Research, not advice.
À propos
YD Bio Limited Ordinary Shares
- Nom
- YD Bio Limited Ordinary Shares
- Secteur
- Healthcare
- Industrie
- Biotechnology
- Bourse
- NASDAQ
- Capitalisation
- $350.6M
- Employés
- 14
- PDG
- Ethan Shen
- Site web
- https://www.ydesgroup.com
- Marché
- ARCTASMBCADLFULCNBTXOBIO
YD Bio Limited, a biopharmaceutical company, focuses on regulated diagnostics, life science clinical services, and healthcare product commercialization in the United States and Taiwan. The company offers eye disease treatment products, 3D LensMate Artificial Tears, a natural tear-mimicking lubricant that moisturizes the eyes and relieves dry eye symptoms; 3D LensMate Eye Drops, an ophthalmic solution to alleviate symptoms of dry eye syndrome, including irritation, foreign body sensation, and eye fatigue; and LSC Eye Drug/Injection, an injectable ophthalmic drug is being developed for the treatment of various retinal and macular disorders, such as age-related macular degeneration, macular edema, choroidal and subretinal neovascularization, and neovascular glaucoma. It also provides Hydrogel (Hioxifilcon A) Soft (Hydrophilic) Contact Lens, a spherical and aspherical lenses. In addition, the company supplies drugs and medical materials for clinical trials; and operates DNA methylation-based oncology testing programs. Further, it provides life science distribution and clinical trial supply chain services, including procurement, logistics coordination, and compliance-focused support for clinical development programs to pharmaceutical and biotechnology companies. It serves corporate and retail customers. The company was founded in 2013 and is based in Taipei, Taiwan.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
ACHAT TOTAL: 34 178 titres (~128 525,26 $ US)
- Insiders
- Shen Ethan PhD
- Total bought
-
$128,525
Avg buy (VWAP, 90d window) $3.76 vs last close —
- Total sold
-
—
Avg sell (VWAP, 90d window) —
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
- Last activity
- 2026-09-14
- Last synced
-
2026-09-20 09:54:07
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-09-14 | Shen Ethan PhD | Buy · P | 12,700 | $3.85 | $48,895 | Form 4 |
| 2026-09-09 | Shen Ethan PhD | Buy · P | 3,100 | $3.93 | $12,183 | Form 4 |
| 2026-09-04 | Shen Ethan PhD | Buy · P | 18,378 | $3.67 | $67,447 | Form 4 |
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Signal
Neutral signalScored 2026-09-10 Drivers: fundamentals. Moteurs : fondamentaux.
The 0-100 score behind this signal and the full written analysis are part of Plus. See plans.
Neutral signal
Drivers: fundamentals. Moteurs : fondamentaux.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Supports a bullish reading. Open-market purchases outweigh sales
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Narrative Pulls against a bullish reading. Stored narrative reading is in the bearish band
- Timing Unavailable or mixed. No stored price series
- Financial indicators Unavailable or mixed. Current ratio 5.88 · operating margin -883% — readings disagree
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | -7.1% | 30.4% | 43.8% | 0.0% | 0.0% | |
| Ebit Margin | -1392.9% | -271.5% | 5.7% | 0.0% | 0.0% | |
| Ebitda Margin | -1357.8% | -251.0% | 6.4% | 0.0% | 0.0% | |
| Operating Profit Margin | -883.3% | -286.5% | -2.8% | 0.0% | 0.0% | |
| Pretax Profit Margin | -1392.9% | -271.7% | 5.0% | 0.0% | 0.0% | |
| Continuous Operations Profit Margin | -1392.6% | -276.6% | 3.9% | 0.0% | 0.0% | |
| Net Profit Margin | -1392.6% | -276.6% | 3.9% | 0.0% | 0.0% | |
| Bottom Line Profit Margin | -1392.6% | -276.6% | 3.9% | 0.0% | 0.0% | |
| Current Ratio | 5.884 | 13.183 | 0.911 | 0.037 | 0.065 | |
| Quick Ratio | 4.740 | 13.041 | 0.678 | 0.037 | 0.065 | |
| Solvency Ratio | -0.487 | -4.770 | 0.054 | 0.562 | 0.956 | |
| Cash Ratio | 3.655 | 11.907 | 0.292 | 0.003 | 0.003 | |
| Price To Earnings Ratio | -101.583 | -21.500 | 60,200.000 | 29.366 | 20.407 | |
| Price To Earnings Growth Ratio | 1.293 | 0.000 | -602.294 | -0.963 | -0.046 | |
| Forward Price To Earnings Growth Ratio | 1.293 | 0.000 | -602.294 | -0.963 | -0.046 | |
| Price To Earnings Diluted Ratio | -101.583 | -21.500 | 60,200.000 | 29.366 | 20.407 | |
| Price To Earnings Diluted Growth Ratio | 1.293 | 0.000 | -602.294 | -0.963 | -0.046 | |
| Price To Book Ratio | -284.805 | 7.574 | 36,702.999 | 9.992 | 1.617 | |
| Price To Sales Ratio | 1,362.741 | 97.806 | 2,410.380 | 0.000 | 0.000 | |
| Price To Free Cash Flow Ratio | -101.199 | -10.514 | -15,084.790 | -37.019 | -255.888 | |
| Price To Operating Cash Flow Ratio | -123.290 | -27.175 | -15,163.389 | -37.019 | -255.890 | |
| Debt To Assets Ratio | 0.000 | 0.003 | 0.148 | 0.000 | 0.000 | |
| Debt To Equity Ratio | -0.002 | 0.003 | 2.069 | 0.000 | 0.000 | |
| Debt To Capital Ratio | -0.002 | 0.003 | 0.674 | 0.000 | 0.000 | |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Financial Leverage Ratio | -4.825 | 1.042 | 13.969 | 1.601 | 1.084 | |
| Working Capital Turnover Ratio | 0.106 | 0.321 | -0.130 | 0.000 | 0.000 | |
| Operating Cash Flow Ratio | -4.014 | -6.983 | -0.187 | -0.545 | -0.345 | |
| Operating Cash Flow Sales Ratio | -11.053 | -3.599 | -0.159 | 0.000 | 0.000 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.218 | 2.585 | 1.005 | 1.000 | 1.000 | |
| Debt Service Coverage Ratio | 0.000 | -1,229.804 | 0.498 | 0.000 | 0.000 | |
| Interest Coverage Ratio | 0.000 | -1,893.692 | -4.593 | 0.000 | 0.000 | |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | -6,333.855 | -1.622 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | -975.267 | -81.437 | -1.170 | 0.000 | 0.000 | |
| Capital Expenditure Coverage Ratio | -4.581 | -0.631 | -191.921 | 0.000 | -137,683.000 | |
| Dividend Paid And Capex Coverage Ratio | -4.581 | -0.631 | -191.921 | 0.000 | -137,683.000 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -99.627 | -36.540 | 37,935.324 | 29.519 | 20.238 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | -7.1% | ▼-37.5% | ▼-20.5% |
| Ebit Margin | -1392.9% | ▼-1121.3% | ▼-1061.1% |
| Ebitda Margin | -1357.8% | ▼-1106.8% | ▼-1037.3% |
| Operating Profit Margin | -883.3% | ▼-596.9% | ▼-648.8% |
| Pretax Profit Margin | -1392.9% | ▼-1121.2% | ▼-1061.0% |
| Continuous Operations Profit Margin | -1392.6% | ▼-1116.0% | ▼-1059.5% |
| Net Profit Margin | -1392.6% | ▼-1116.0% | ▼-1059.5% |
| Bottom Line Profit Margin | -1392.6% | ▼-1116.0% | ▼-1059.5% |
| Current Ratio | 5.884 | ▼-7.299 | ▲1.868 |
| Quick Ratio | 4.740 | ▼-8.301 | ▲1.028 |
| Solvency Ratio | -0.487 | ▲4.283 | ▲0.250 |
| Cash Ratio | 3.655 | ▼-8.252 | ▲0.483 |
| Price To Earnings Ratio | -101.583 | ▼-80.083 | ▼-12126.921 |
| Price To Earnings Growth Ratio | 1.293 | ▲1.293 | ▲121.695 |
| Forward Price To Earnings Growth Ratio | 1.293 | ▲1.293 | ▲121.695 |
| Price To Earnings Diluted Ratio | -101.583 | ▼-80.083 | ▼-12126.921 |
| Price To Earnings Diluted Growth Ratio | 1.293 | ▲1.293 | ▲121.695 |
| Price To Book Ratio | -284.805 | ▼-292.379 | ▼-7572.280 |
| Price To Sales Ratio | 1362.741 | ▲1264.934 | ▲588.555 |
| Price To Free Cash Flow Ratio | -101.199 | ▼-90.685 | ▲2996.683 |
| Price To Operating Cash Flow Ratio | -123.290 | ▼-96.114 | ▲2998.063 |
| Debt To Assets Ratio | 0.001 | ▼-0.003 | ▼-0.030 |
| Debt To Equity Ratio | -0.002 | ▼-0.006 | ▼-0.416 |
| Debt To Capital Ratio | -0.002 | ▼-0.006 | ▼-0.137 |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 |
| Financial Leverage Ratio | -4.825 | ▼-5.867 | ▼-7.399 |
| Working Capital Turnover Ratio | 0.106 | ▼-0.215 | ▲0.047 |
| Operating Cash Flow Ratio | -4.014 | ▲2.969 | ▼-1.599 |
| Operating Cash Flow Sales Ratio | -11.053 | ▼-7.454 | ▼-8.091 |
| Free Cash Flow Operating Cash Flow Ratio | 1.218 | ▼-1.367 | ▼-0.143 |
| Debt Service Coverage Ratio | 0.000 | ▲1229.804 | ▲245.861 |
| Interest Coverage Ratio | 0.000 | ▲1893.692 | ▲379.657 |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | ▲6333.855 | ▲1267.095 |
| Operating Cash Flow Coverage Ratio | -975.267 | ▼-893.830 | ▼-763.692 |
| Capital Expenditure Coverage Ratio | -4.581 | ▼-3.950 | ▲27571.446 |
| Dividend Paid And Capex Coverage Ratio | -4.581 | ▼-3.950 | ▲27571.446 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -99.627 | ▼-63.087 | ▼-7669.410 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $813.3M | $49.9M | $843.9M | $111.9M | $176.2M | |
| Enterprise value | $807.3M | $46.8M | $843.9M | $111.9M | $176.2M | |
| EV / Sales | 1352.69x | 91.71x | 2410.27x | 0.00x | 0.00x | |
| EV / Op. cash flow | -122.38x | -25.48x | -15162.68x | -37.02x | -255.88x | |
| EV / Free cash flow | -100.45x | -9.86x | -15084.08x | -37.02x | -255.88x | |
| EV / EBITDA | -99.63x | -36.54x | 37935.32x | 29.52x | 20.24x | |
| Net debt / EBITDA | 0.74x | 2.43x | -1.78x | -0.00x | -0.00x | |
| Current ratio | 5.88x | 13.18x | 0.91x | 0.04x | 0.07x | |
| Income quality | 0.79x | 1.30x | -4.10x | -0.80x | -0.08x | |
| Graham number | — | — | $0 | $3 | $10 | |
| Graham net-net | -$0 | $1 | -$0 | -$1 | -$1 | |
| Tax burden | 100.0% | 101.8% | 76.8% | 99.9% | 100.0% | |
| Interest burden | 100.0% | 100.1% | 89.2% | 100.0% | 100.0% | |
| Working capital | $8.0M | $3.2M | -$26K | -$5.3M | -$1.9M | |
| Invested capital | $10.7M | $6.0M | -$12K | -$5.3M | -$1.9M | |
| Return on assets | -60.3% | -20.6% | 4.2% | 21.1% | 7.4% | |
| Operating ROA | -51.1% | -40.7% | -0.1% | -3.4% | -1.5% | |
| Return on tangible assets | -74.4% | -33.7% | 4.2% | 21.1% | 7.4% | |
| Return on equity | 291.0% | -21.4% | 59.0% | 33.8% | 8.0% | |
| Return on invested capital | -43.4% | -22.1% | -10.7% | -18.8% | -1.5% | |
| Return on capital employed | -43.4% | -22.1% | -42.8% | -18.8% | -1.5% | |
| Earnings yield | -1.0% | -2.8% | 0.0% | 3.4% | 4.9% | |
| Free cash flow yield | -1.0% | -9.5% | -0.0% | -2.7% | -0.4% | |
| Capex / Op. cash flow | -21.8% | -158.5% | -0.5% | 0.0% | -0.0% | |
| Capex / Depreciation | 687.2% | 2779.4% | 11.8% | 0.0% | 0.0% | |
| Capex / Sales | 241.3% | 570.4% | 0.1% | 0.0% | 0.0% | |
| SG&A / Sales | 607.8% | 220.7% | 45.9% | 0.0% | 0.0% | |
| R&D / Sales | 268.4% | 96.3% | 0.0% | 0.0% | 0.0% | |
| Stock comp / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Intangibles / Total assets | 18.9% | 39.0% | 0.0% | 0.0% | 0.0% | |
| Days sales outstanding | 436d | 188d | 103d | 0d | 0d | |
| Days payables outstanding | 236d | 27d | 33d | 0d | 0d | |
| Operating cycle | 1509d | 226d | 231d | 0d | 0d | |
| Cash conversion cycle | 1273d | 199d | 198d | 0d | 0d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▲+1529.3%EV / Sales ▲+1374.9%EV / EBITDA ▼-172.7%EV / Op. cash flow ▼-96.898Earnings yield ▲+0.018
Profitability
Return on equity ▲+3.125Return on assets ▼-0.398Return on invested capital ▼-0.213Return on capital employed ▼-0.213Operating ROA ▼-0.104Income quality ▼-0.508Tax burden ▼-0.018
Efficiency
Days sales outstanding ▲+247.657Days payables outstanding ▲+208.589Operating cycle ▲+1282.930Cash conversion cycle ▲+1074.341Capex / Sales ▼-3.291R&D / Sales ▲+1.722
Balance-sheet strength
Current ratio ▼-7.299Net debt / EBITDA ▼-1.687Working capital ▲+4821790.000Invested capital ▲+4731227.000Intangibles / Total assets ▼-0.201
Change over 5 years
Valuation
Market cap ▲+361.7%EV / Sales n/aEV / EBITDA ▼-592.3%EV / Op. cash flow ▲+133.502Earnings yield ▼-0.060
Profitability
Return on equity ▲+2.831Return on assets ▼-0.677Return on invested capital ▼-0.419Return on capital employed ▼-0.420Operating ROA ▼-0.496Income quality ▲+0.873Tax burden -0.000
Efficiency
Days sales outstanding n/aDays payables outstanding n/aOperating cycle n/aCash conversion cycle n/aCapex / Sales n/aR&D / Sales n/a
Balance-sheet strength
Current ratio ▲+5.819Net debt / EBITDA ▲+0.741Working capital ▲+9893814.000Invested capital ▲+12571363.000Intangibles / Total assets n/a
Employee count
No employee-count data synced.
Peer market caps
Recent news
- 2026-08-31 YD Bio Limited Reports Unaudited Financial Results for the Six Months Ended June 30, 2026 TAIPEI, Taiwan, Aug. 31, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation–based cancer detection technology and ophthalmologic innovations, today announced its financial results for the six months ended June 30, 2026.
- 2026-08-25 YD Bio Announces Peer-Reviewed Publication in Nutrients, Co-Authored with Physicians from the Taiwan Chronic Disease Healthcare Association and the Future Health Institute TAIPEI, Taiwan, Aug. 25, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation–based cancer detection technology and ophthalmologic innovations, today announced the publication of a peer-reviewed review article in Nutrients, an international open-access journal published by MDPI (Multidisciplinary Digital Publishing Institute). The article, titled “Beyond Bone Health: Exploring the ‘Heart–Brain–Bone'' Axis Modulated by Lipid-Soluble Nutrients (Omega-3, Vitamin D3, and Vitamin K2),” was co-authored by members of the Company''s scientific team together with physicians associated with the Taiwan Chronic Disease Healthcare Association (“CDHA”), the Future Health Institute (“FHI”), and the Department of Neurosurgery at Taipei Medical University Hospital, among others.
- 2026-08-16 Head-To-Head Comparison: YD Bio (NASDAQ:YDES) versus Arbutus Biopharma (NASDAQ:ABUS) Arbutus Biopharma (NASDAQ: ABUS - Get Free Report) and YD Bio (NASDAQ: YDES - Get Free Report) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, institutional ownership, dividends, risk, profitability, analyst recommendations and valuation. Profitability This table compares Arbutus Biopharma and
- 2026-07-28 YD Bio Launches Cross-Border Cancer Testing Pilot with Numia Health to Evaluate Expanded Access to Molecular Diagnostics in Canada The six-month pilot is designed to evaluate the potential scalability of bringing physician-ordered, blood-based OkaiDx laboratory-developed tests to patients in Canada Taipei, Taiwan, July 28, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation–based cancer detection technology and ophthalmologic innovations, today announced the launch of a six-month pilot collaboration (the “Pilot”) pursuant to that certain Pilot Service Agreement, dated as of July 23, 2026 (the “Agreement”), by and among YD Bio, YD Bio US Inc., a subsidiary of YD Bio (“YD Bio US”), EG BioMed US Inc., an affiliate of YD Bio (“EG BioMed US”), and Numia Health Inc., a British Columbia–based healthcare services provider (“Numia Health”), to establish a cross-border clinical workflow designed to support physician-ordered, blood-based cancer testing for eligible patients in British Columbia, Canada. Under the Agreement, the parties intend to evaluate an integrated clinical pathway that combines physician access, certified mobile blood collection, cross-border specimen logistics, and laboratory testing at EG BioMed US''s CLIA-certified, CAP-accredited laboratory in Bothell, Washington (the “Laboratory”).
- 2026-07-23 YD Bio and EG BioMed Conclude Successful Exhibition at BIO Asia-Taiwan 2026, Highlighting Innovations in Ophthalmology, Oncology Diagnostics, and Clinical Services Taipei, Taiwan, July 23, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations, today announced the successful conclusion of YD Bio''s and its affiliate EG BioMed Co., Ltd.''s (“EG BioMed”) participation at BIO Asia-Taiwan 2026, an international industry conference held in Taiwan, at the Washington State Pavilion on July 19, 2026.
- 2026-07-02 YD Bio Expands U.S. Laboratory Footprint to 46 States, Strengthening DNA-Methylation Early Cancer Detection Operations Taipei, Taiwan, July 02, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited ("YD Bio" or the "Company") (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations, today announced that its affiliate, EG BioMed US Inc. , a Delaware corporation ("EG BioMed US"), has obtained out-of-state clinical laboratory licenses in Rhode Island and Pennsylvania for its CLIA-certified, CAP-accredited laboratory in Bothell, Washington (CLIA #50D2316600), reinforcing the Company''s transition from a collection of technologies to a platform-based biotechnology company anchored in clinically derived molecular data.
- 2026-07-02 YD Bio Expands U.S. Laboratory Footprint to 46 States, Strengthening DNA-Methylation Early Cancer Detection Operations Taipei, Taiwan, July 02, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation–based cancer detection technology and ophthalmologic innovations, today announced that its affiliate, EG BioMed US Inc., a Delaware corporation (“EG BioMed US”), has obtained out-of-state clinical laboratory licenses in Rhode Island and Pennsylvania for its CLIA-certified, CAP-accredited laboratory in Bothell, Washington (CLIA #50D2316600), reinforcing the Company''s transition from a collection of technologies to a platform-based biotechnology company anchored in clinically derived molecular data.